Eif4b, CPTAC-3827 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

non-CPTAC-3827: View additional SILPTAPR data

10 20 30 40 50
MAASAKKKNK KGKTISLTDF LAEDGGTGGG STYVPKPVSW ADETDDLEGD
60 70 80 90 100
VSTTWHSNDD DVYRAPPIDR SILPTAPRAA REPNIDRSRL PKSPPYTAFL
110 120 130 140 150
GNLPYDVTED SIKDFFRGLN ISAVRLPREP SNPDRLKGFG YAEFEDLDSL
160 170 180 190 200
LSALSLNEES LGNRRIRVDV ADQAQDKDRD DRSFGRDRNR DSDKTDTDWR
210 220 230 240 250
ARPTTDSFDD YPPRRGDDSF GDKYRDRYDS DRYRDGYRDG YRDGPRRDMD
260 270 280 290 300
RYGGRDRYDD RGSRDYDRGY DSRIGSGRRA FGSGYRRDDD YRGGGDRYED
310 320 330 340 350
RYDRRDDRSW SSRDDYSRDD YRRDDRGPPQ RPRLNLKPRS APKEDDASAS
360 370 380 390 400
TSQSSRAASI FGGAKPVDTA AREREVEERL QKEQEKLQRQ LDEPKLDRRP
410 420 430 440 450
RERHPSWRSE ETQERERSRT GSESSQTGAS ATSGRNTRRR ESEKSLENET
460 470 480 490 500
LNKEEDCHSP TSKPPKPDQP LKVMPAPPPK ENAWVKRSSN PPARSQSSDT
510 520 530 540 550
EQPSPTSGGG KVAAVQPPEE GPSRKDGNKV DVVGATQGQA GSCSRGPGDG
560 570 580 590 600
GSRDHWKDLD RKDGKKDQDS RSAPEPKKPE ENPASKFSSA SKYAALSVDG
610 611
EDEDEGDDCT E

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader


Assay Details for non-CPTAC-3827 Collapse assay details

Data source: Panorama

Official Gene Symbol

Eif4b

Peptide Sequence

SILPTAPR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

71

Peptide End

78

CPTAC ID

non-CPTAC-3827

Peptide Molecular Mass

853.5022

Species

Mus musculus (Mouse)

Assay Type

Direct MRM

Matrix

Plasma

Submitting Laboratory

UVic-Genome BC Proteomics Centre

Submitting Lab PI

Christoph Borchers


Publication

View Details (opens in a new window)

Molecular phenotyping of laboratory mouse strains using 500 multiple reaction monitoring mass spectrometry plasma assays. Michaud SA, Sinclair NJ, Petrošová H, Palmer AL, Pistawka AJ, Zhang S, Hardie DB, Mohammed Y Eshghi A1, Richard VR, Sickmann A, Borchers CH. Commun Biol. 2018 Jun 27;1:78. doi: 10.1038/s42003-018-0087-6. eCollection 2018.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

Agilent 6490/6495 QQQ

Internal Standard

synthetic peptide

Peptide Standard Purity

>80%

Peptide Standard Label Type

13C and 15N at C-terminus R

LC

1290 LC (Agilent)

Column Packing

Zorbax Eclipse Plus C18, 1.8 µm

Column Dimensions

2.1 x 150 mm

Flow Rate

400 µL/min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | b3 (1+) | 15 | 4.4 | 3.1 | 17 | 8 | 3.4 | 22.7 | 9.1 | 4.6 | 15 | 15 | 15 | | b2 (1+) | 8.2 | 4.6 | 5.2 | 14.2 | 10 | 6.1 | 16.4 | 11 | 8 | 15 | 15 | 15 | | y5 (2+) | 10.3 | 7.7 | 2.2 | 12.7 | 10.8 | 4.8 | 16.4 | 13.3 | 5.3 | 15 | 15 | 15 | | y6 (2+) | 18.9 | 5 | 4.2 | 14 | 9.1 | 4.5 | 23.5 | 10.4 | 6.2 | 15 | 15 | 15 | | y5 (1+) | 9.8 | 3.4 | 2.4 | 12 | 9.8 | 6.3 | 15.5 | 10.4 | 6.7 | 15 | 15 | 15 | | sum | 4.3 | 2.3 | 1.8 | 9 | 8.4 | 4.4 | 10 | 8.7 | 4.8 | 15 | 15 | 15 |



Additional Resources and Comments